Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 May 21;5(5):CD015530.
doi: 10.1002/14651858.CD015530.pub2.

Vaccines for preventing infections in adults with haematological malignancies

Ana-Mihaela Zorger  1 , Caroline Hirsch  1 , Mandy Baumann  1 , Merit Feldmann  1 , Paul J Bröckelmann  2   3 , Sibylle Mellinghoff  2   4   5 , Ina Monsef  1 , Nicole Skoetz  1 , Nina Kreuzberger  1
Affiliations
Review

Vaccines for preventing infections in adults with haematological malignancies

Ana-Mihaela Zorger et al. Cochrane Database Syst Rev. .

Abstract

Background: Vaccination aims to prevent infections. People who are immunocompromised, such as those with haematological malignancies, often experience higher immunosuppression, increasing their vulnerability to infections compared to individuals with solid tumours or healthy individuals.

Objectives: The aim of this review is to summarise and evaluate the benefits and risks of vaccines for preventing infections in adults with haematological malignancies.

Search methods: We conducted a comprehensive systematic search in CENTRAL, MEDLINE, Embase, LILACS, and Web of Science on 2 December 2024 for randomised controlled trials (RCTs) and for controlled non-randomised studies of interventions (NRSIs). We also searched ClinicalTrials.gov, WHO (World Health Organization) International Clinical Trials Registry Platform (ICTRP), and the Cochrane COVID-19 Study Register.

Selection criteria: We included RCTs and controlled NRSIs evaluating the preventive effect of vaccines on outcomes prioritised by clinical experts, patients, and patient representatives. The prioritised outcomes for adults (≥ 18 years) with haematological malignancies (excluding those receiving cellular therapies) were infection incidence, all-cause mortality, quality of life, adverse events of any grade, serious adverse events, and adverse events of special interest. We looked for studies that evaluated a broad range of vaccine types (e.g. COVID-19, diphtheria, Haemophilus influenzae type b, hepatitis B, herpes zoster, influenza, Neisseria meningitidis, pertussis, polio, Streptococcus pneumoniae, or tetanus), but we excluded live-attenuated vaccines.

Data collection and analysis: We followed current Cochrane methodological standards in the conduct of this review. We assessed the risk of bias using the Cochrane risk of bias 2 tool (RoB 2) for RCTs and Risk Of Bias In Non-randomised Studies - of Interventions (ROBINS-I) for controlled NRSIs.

Main results: We included six studies (four RCTs, two controlled NRSIs) with a total of 25,886 participants. We present the RCT results here and the NRSI findings from NRSIs in the full review. We judged one RCT on herpes zoster to be at low risk of bias overall, and we had 'some concerns' about bias in the other RCT on herpes zoster. We had 'some concerns' about bias in the RCTs on COVID-19 and influenza vaccines. Herpes zoster vaccines Two RCTs, involving 3067 participants with a range of haematological malignancies, evaluated vaccines for preventing herpes zoster compared to placebo or no vaccine. Vaccines may reduce herpes zoster incidence up to 21 months post-vaccination, although the 95% CI includes the possibility of no effect (4% versus 6%; RR 0.40, 95% CI 0.07 to 2.23; 2 RCTs, 3067 participants; low-certainty evidence). Vaccines probably have little to no effect on all-cause mortality up to 28 days post-vaccination (2.7% versus 2.6%; RR 1.03, 95% CI 0.65 to 1.64; 2548 participants; moderate-certainty evidence). Vaccines slightly increase any-grade adverse events within 30 days (RR 1.12, 95% CI 1.07 to 1.18; 3110 participants; high-certainty evidence), but probably do not increase serious adverse events within 12 months (23% versus 29%; RR 0.79, 95% CI 0.60 to 1.05; 562 participants; moderate-certainty evidence) after vaccination. Vaccines increase injection site adverse events substantially (40% versus 13%; RR 3.07, 95% CI 2.62 to 3.59; high-certainty evidence) and also increase systemic adverse events (10% versus 6%; RR 1.82, 95% CI 1.38 to 2.40; high-certainty evidence), as measured in 2548 participants within 28 days post-vaccination. Neither RCT reported quality of life. COVID-19 vaccines One RCT, involving 95 participants with lymphoma, leukaemia or myeloma, evaluated the BNT162b2 COVID-19 vaccine compared to placebo or no vaccine. Evidence about the effect of BNT162b2 vaccine on the incidence of COVID-19 up to six months after the second dose compared to placebo or no vaccine remains very uncertain (2.2% versus 2%; RR 1.11, 95% CI 0.07 to 17.25; 1 RCT, 95 participants; very low certainty evidence). Regarding safety data (mixed population including both solid tumours and haematological malignancies), BNT162b2 vaccine probably increases the number of participants with any grade adverse events (35% versus 17.5%; RR 1.99, 95% CI 1.71 to 2.30; 1 RCT, 2328 participants; moderate-certainty evidence) and there may be little to no difference concerning the number of participants experiencing serious adverse events (2.4% versus 1.7%; RR 1.43, 95% CI 0.80 to 2.54; 1 RCT, 2328 participants; low-certainty evidence). The RCT did not report all-cause mortality, quality of life, injection site adverse events or systemic adverse events. Influenza vaccines No RCTs evaluated an influenza vaccine versus placebo or no vaccine. One RCT, involving 122 participants with plasma cell disorders, evaluated different dosing regimens for an influenza vaccine on the incidence of influenza infection. Evidence is very uncertain regarding the effect of two doses of high-dose trivalent inactivated influenza vaccine compared to one dose (with strength based on age) of influenza vaccination on the incidence of infection within the 2015 to 2016 flu season (4% versus 8%; RR 0.49, 95% CI 0.11 to 2.08; very low-certainty evidence). The RCT did not report all-cause mortality, quality of life, any-grade or serious adverse events, or injection site or systemic adverse events.

Authors' conclusions: The evidence on vaccines for preventing infections in adults with haematological malignancies is limited and uncertain. Herpes zoster vaccines may reduce infection risk for up to 21 months, but the certainty of the evidence is low. While there is a considerable increase in short-term adverse events (high-certainty evidence), no increase in serious adverse events was observed at up to 12 months (moderate-certainty evidence). Data on long-term impacts on other outcomes are lacking. For COVID-19 and influenza vaccines, the evidence is very uncertain. We found no studies that could be included in the review of vaccines for our other infectious diseases of interest: diphtheria, Haemophilus influenzae type b (Hib), hepatitis B, Neisseria meningitidis, pertussis, polio, Streptococcus pneumoniae, or tetanus. Our review underscores the need for high-quality RCTs and controlled NRSIs with better reporting, larger samples, longer follow-ups, and a focus on patient-relevant outcomes, such as quality of life and long-term safety. A robust and continuously updated evidence base is essential to guide clinical and public health decisions.

Trial registration: ClinicalTrials.gov NCT01767467 NCT01254630 NCT04368728 NCT00535236 NCT03619252 NCT01892618 NCT05415267 NCT05417165 NCT05556720 NCT05831787.

PubMed Disclaimer

Conflict of interest statement

AMZ: staff at Cochrane Evidence Synthesis Unit Germany/UK and Cochrane Haematology, but not involved in the editorial process

CH: deputy head of Cochrane Evidence Synthesis Unit Germany/UK and Managing Editor at Cochrane Haematology, but not involved in the editorial process

MB: staff at Cochrane Haematology, but not involved in the editorial process

MF: staff at Cochrane Haematology, but not involved in the editorial process

PJB: BeiGene (grant/contract), Bristol‐Meyers Squibb Foundation (grant/contract), Celgene (travel), Merck Sharp and Dohme (consultant), Stemline Therapeutics (consultant), Takeda Oncology (consultant)

SM: Gilead Foundation (travel), Octapharma USA Inc (consultant)

IM: Information Specialist at Cochrane Evidence Synthesis Unit Germany/UK and Cochrane Haematology, but not involved in the editorial process

NS: lead of Cochrane Evidence Synthesis Unit Germany/UK and Co‐ordinating Editor of Cochrane Haematology, but not involved in the editorial process

NK: staff at Cochrane Evidence Synthesis Unit Germany/UK and Cochrane Haematology, but not involved in the editorial process

Update of

  • doi: 10.1002/14651858.CD015530

Similar articles

See all similar articles

Cited by

References

References to studies included in this review

Amdisen 2024 {published and unpublished data}
    1. Amdisen L, Pedersen L, Abildgaard N, Stabell Benn C, Cronin-Fenton D, Sörup S, et al. Influenza vaccine effectiveness in immunocompromised patients with cancer: a Danish nationwide register-based cohort study. Cancer 2024;131(1):e35574. [DOI: 10.1002/cncr.35574] - DOI - PMC - PubMed
    1. Amdisen L. Subgroup outcome data for population with haematological malignancies [personal communication]. Email to: A-M Zorger 23 January 2025.
Barbui 2022 {published data only}
    1. Barbui T, Carobbio A, Ghirardi A, Iurlo A, De Stefano V, Sobas MA, et al. Breakthrough infections in MPN-COVID vaccinated patients. Blood Cancer Journal 2022;12(11):154. [DOI: 10.1038/s41408-022-00749-8] - DOI - PMC - PubMed
    1. Barbui T, Carobbio A, Ghirardi A, Iurlo A, De Stefano V, Sobas MA, et al. Protection against breakthrough delta/omicron variants in vaccinated patients with myeloproliferative neoplasms (MPN). Blood 2022;140(Supplement 1):6815–8. [DOI: 10.1182/blood-2022-158902] - DOI
Branagan 2016 {published data only}
    1. Branagan AR, Duffy E, Parker TL, Seropian S, Foster C, Zhang L, et al. Lower rates of influenza infection following two dose series of high dose vaccination in plasma cell disorders: results of a randomized, double-blind, placebo-assisted clinical trial. Blood 2016;128(22):2139. [DOI: 10.1182/blood.V128.22.2139.2139] - DOI
Dagnew 2019 {published data only}2012‐003438‐18
    1. Dagnew AF, Ilhan O, Lee WS, Woszczyk D, Kwak JY, Bowcock S, et al. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis. Lancet Infectious Diseases 2019;19(9):988-1000. [DOI: 10.1016/S1473-3099(19)30163-X] - DOI - PubMed
    1. Dagnew AF, Ilhan O, Lee WS, Woszczyk D, Kwak JY, Bowcock S, et al. Immunogenicity, safety, and post-hoc efficacy assessment of the adjuvanted recombinant zoster vaccine in adults with hematologic malignancies: a phase 3, randomized clinical trial. Open Forum Infectious Diseases 2018;5:9‐10. [DOI: 10.1093/ofid/ofy209.019] - DOI
    1. EUCTR2012-003438-18-SE. Study to check safety and immune response of GSK Biologicals' Herpes Zoster vaccine GSK1437173A in adults aged 18 years and older with blood cancers. https://trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2012-003438-18-SE (first received 13 February 2023).
    1. NCT01767467. Study to assess the safety and immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) vaccine in adults aged 18 years and older with blood cancers. https://clinicaltrials.gov/study/NCT01767467 (first received 18 February 2023).
    1. Oostvogels L. Immunogenicity and safety of an adjuvanted herpes zoster subunit candidate vaccine in adults with hematologic malignancies: a phase III, randomized clinical trial. In: Open Forum Infectious Diseases. Vol. 4. 2017:S415.
Mullane 2019 {published data only}023156‐89‐ES2010‐023156‐89‐AT
    1. Anonymous. Correction to safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a two-arm, randomised, double-blind, phase 3 trial (The Lancet Infectious Diseases (2019) 19(9) (1001-1012), (S147330991930310X), (10.1016/S1473-3099(19)30310-X)). Lancet Infectious Diseases 2019;19(10):e337. [DOI: 10.1016/S1473-3099%2819%2930469-4] - DOI - PubMed
    1. Boeckh MJ, Arvin AM, Mullane KM, Camacho LH, Winston DJ, Morrison VA, et al. Immunogenicity of inactivated varicella zoster vaccine in autologous hematopoietic stem cell transplant recipients and patients with solid or hematologic cancer. Open Forum Infectious Diseases 2020;7(7):ofaa172. [DOI: 10.1093/ofid/ofaa172] - DOI - PMC - PubMed
    1. EUCTR-023156-89-ES. A phase III randomized, placebo-controlled, clinical trial to study the safety and efficacy of V212 in adult patients with solid tumor or hematologic malignancy. https://clinicaltrials.gov/study/NCT01767467 (first received 27 December 2010).
    1. EUCTR2010-023156-89-AT. A phase III randomized, placebo-controlled, clinical trial to study the safety and efficacy of V212 in adult patients with solid tumor or hematologic malignancy. https://trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2010-023156-89-AT (first received 13 February 2023).
    1. Mullane KM, Morrison VA, Camacho LH, Arvin A, McNeil SA, Durrand J, et al. Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a two-arm, randomised, double-blind, phase 3 trial. Lancet Infectious Diseases 2019;19(9):1001-12. [DOI: 10.1016/S1473-3099(19)30310-X] - DOI - PubMed
Thomas 2022 {published data only}
    1. Fraiman J, Erviti J, Jones M, Greenland S, Whelan P, Kaplan RM, et al. Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults. Vaccine 2022;40(40):5798-805. [DOI: 10.1016/j.vaccine.2022.08.036] - DOI - PMC - PubMed
    1. Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtmann A, Lockhart S, et al. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature 2020;586:589-93. [DOI: 10.1038/s41586-020-2639-4] - DOI - PubMed
    1. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. New England Journal of Medicine 2020;383(27):2603-15. [DOI: 10.1056/NEJMoa2034577] - DOI - PMC - PubMed
    1. Thomas SJ, Moreira ED, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months. New England Journal of Medicine 2021;385(19):1761-73. [DOI: 10.1056/NEJMoa2110345] - DOI - PMC - PubMed
    1. Thomas SJ, Perez JL, Lockhart SP, Hariharan S, Kitchin N, Bailey R, et al. 1558O COVID-19 vaccine in participants (ptcpts) with cancer: subgroup analysis of efficacy/safety from a global phase III randomized trial of the BNT162b2 (tozinameran) mRNA vaccine. Annals of Oncology 2021;32(Suppl 5):1129. [DOI: 10.1016/j.annonc.2021.08.1551] - DOI

References to studies excluded from this review

ACTRN12622000411741 {published data only}
    1. ACTRN12622000411741. COVID-19 vaccine boost to enhance immunity in healthy adults aged 18-65 (The Booster Study). https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=383572&... (first received 10 March 2022).
Advani 2021 {published data only}
    1. Advani P, Chumsri S, Pai T, Li Z, Sharma A, Parent E. Temporal metabolic response to mRNA COVID-19 vaccinations in oncology patients. Annals of Nuclear Medicine 2021;35(11):1264-69. [DOI: 10.1007/s12149-021-01675-8] - DOI - PMC - PubMed
Barrientos‐Flores 2024 {published data only}
    1. Barrientos-Flores C, Vilar-Compte D, Martinez-Rivera N, Villasenor R, Martin-Onraet A. SARS-CoV-2 vaccination in patients with cancer and COVID-19 in Mexico. Vaccines (Basel) 2024;12(10):1163. [DOI: 10.3390/vaccines12101163] - DOI - PMC - PubMed
EUCTR2021‐002693‐10‐AT {published data only}https://trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2021-002693-10-AT
    1. EUCTR2021-002693-10-AT. A phase II study to evaluate safety and efficacy to a third vaccination with an mRNA or vector vaccine in patients under immunosuppressive therapy no or reduced responds to standard mRNA SARS-CoV-2 (Covid-19) vaccination. https://trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2021-002693-10-AT (first received 8 November 2021).
ISRCTN16865769 {published data only}
    1. ISRCTN16865769. Investigating COVID-19 infection in patients with acute myeloid leukaemia (AML) undergoing chemotherapy. https://trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN16865769 (first received 28 November 2022).
Mullane 2013 {published data only}
    1. Mullane KM, Mullane MR, Wong BMY, Zhao Y, Sterling T, Manoff S, et al. Safety and immunogenicity of heat-treated zoster vaccine (ZVHT) in adults with solid tumor malignancy (STM). Journal of Clinical Oncology 2011;29(15 SUPPL. 1):1375-85.
    1. Mullane KM, Winston DJ, Wertheim MS, Betts RF, Poretz DM, Camacho LH, et al. Safety and immunogenicity of heat-treated zoster vaccine (ZVHT) in immunocompromised adults. Journal of Infectious Diseases 2013;208(9):1375-85. [DOI: 10.1093/infdis/jit344] - DOI - PubMed
    1. NCT00535236. A study of an investigational V212/heat-treated varicella-zoster virus (VZV) vaccine in immunocompromised adults (V212-002). https://clinicaltrials.gov/show/NCT00535236 (first received 18 February 2023).
Musto 2024 {published data only}
    1. Musto P, Garcia JS, Sgherza N, Bergantim R, Farina F, Seval GC, et al. Survival in multiple myeloma and SARS-COV-2 infection through the COVID-19 pandemic: results from the EPICOVIDEHA registry. Hematological Oncology 2023;42(1):e3240. [DOI: 10.1002/hon.3240] - DOI - PubMed
NCT04918940 {published data only}
    1. NCT04918940. Efficacy of COVID-19 vaccination in patients treated with anti-CD20 for follicular lymphoma or mantle cell lymphoma (VAXIMAB). https://classic.clinicaltrials.gov/ct2/show/NCT04918940 (first received 9 June 2021).
OnCovid {published data only}
    1. Cortellini A, Aguilar-Company J, Salazar R, Bower M, Sita-Lumsden A, Plaja A, et al. Natural immunity to SARS-CoV-2 and breakthrough infections in vaccinated and unvaccinated patients with cancer. British Journal of Cancer 2022;127(10):1787-92. [DOI: 10.1038/s41416-022-01952-x] - DOI - PMC - PubMed
    1. Pinato DJ, Aguilar-Company J, Ferrante D, Hanbury GH, Bower M, Salazar R, et al. Clinical effectiveness of SARS-CoV-2 vaccines and booster doses in patients with cancer: an analysis from the European OnCovid registry. Journal of Clinial Oncology 2022;40(16):e18725. [DOI: 10.1200/JCO.2022.40.16_suppl.e18725] - DOI
    1. Pinato DJ, Ferrante D, Aguilar-Company J, Bower M, Salazar R, Mirallas O, et al. Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer. European Journal of Cancer 2022;171:64-74. [DOI: 10.1016/j.ejca.2022.04.036] - DOI - PMC - PubMed
Sherman 2024 {published data only}
    1. Sherman A, Tuan J, Cantos VD, Adeyiga O, Mahoney S, Ortega-Villa AM, et al. COVID-19 vaccine efficacy in participants with weakened immune systems from four randomized-controlled trials. Clinical Infectious Diseases 2024;79(2):364-74. [DOI: 10.1093/cid/ciae192] - DOI - PMC - PubMed
Sieghart 2022 {published data only}
    1. Mrak D, Sieghart D, Simader E, Tobudic S, Radner H, Mandl P, et al. Heterologous vector versus homologous mRNA COVID-19 booster vaccination in non-seroconverted immunosuppressed patients: a randomized controlled trial. Nature Communications 2022;13(1):5362. [DOI: 10.1038/s41467-022-33036-y] - DOI - PMC - PubMed
Stoma 2020 {published data only}
    1. NCT03619252. Pneumococcal vaccination of multiple myeloma patients on novel agents. https://clinicaltrials.gov/show/NCT03619252 (first received 7 August 2018).
    1. Stoma I, Iskrou I, Lendzina I, Trubkina A, Charniak V, Gerasimovich V, et al. How to prevent pneumonias in patients with multiple myeloma on novel agents: the new regimen of pneumococcal vaccination. Hemasphere 2020;4 (Supplement 1):931. [DOI: 10.1097/HS9.0000000000000404] - DOI
    1. Stoma I, Karpov I, Iskrov I, Lendina I, Trubkina A, Uss A. Efficacy of pneumococcal vaccination in patients with multiple myeloma receiving novel agents: results of a prospective clinical study. International Journal of Infectious Diseases 2020;101 (Supplement 1):470. [DOI: 10.1016/j.ijid.2020.09.1232] - DOI
    1. Stoma I, Karpov I, Iskrov I, Lendina I, Uss A. Clinical efficacy of pneumococcal vaccination in multiple myeloma patients on novel agents: results of a prospective clinical study. Vaccine 2020;38(30):4713-16. [DOI: 10.1016/j.vaccine.2020.05.024] - DOI - PubMed
Teh 2021 {published data only}
    1. Teh B, Leung V, Mordant F, Sullivan S, Joyce T, Harrison S. A randomized trial of two 2-dose influenza vaccination strategies for patients following autologous hematopoietic stem cell transplantation. Clinical Infectious Diseases 2021;73(11):e4269-77. [DOI: 10.1093/cid/ciaa1711] - DOI - PubMed
Villa 2013 {published data only}
    1. Villa D, Gubbay J, Sutherland DR, Laister R, McGeer A, Cooper C, et al. Evaluation of 2009 pandemic H1N1 influenza vaccination in adults with lymphoid malignancies receiving chemotherapy or following autologous stem cell transplant 322. Leukemia & Lymphoma 2013;54(7):1387-95. [DOI: 10.3109/10428194.2012.742524] - DOI - PubMed
    1. Villa D. Population details [personal communication]. Email to: A-M Zorger 25 July 2023.
Woyach 2019 {published data only}
    1. Awan FT, Thangavadivel S, Weiss D, Wei L, Woyach JA, Rogers KA, et al. A phase 2 trial of early intervention with ibrutinib in patients with asymptomatic, high-risk CLL. Blood 2017;130:1748. [DOI: 10.1182/blood.V130.Suppl_1.1748.1748] - DOI
    1. Woyach J, Thangavadivel S, Weiss D, Wei L, McLaughlin E, Rogers K, et al. Final results of a phase 2 trial of early intervention ibrutinib with vaccinations in patients with asymptomatic, high-risk CLL. Blood 2019;134 (Supplement 1):1759. [DOI: 10.1182/blood-2019-131099] - DOI

References to studies awaiting assessment

Bettinger 2022 {published data only}
    1. Bettinger JA, Sadarangani M, De Serres G, Valiquette L, Vanderkooi OG, Kellner JD, et al. The Canadian national vaccine safety network: surveillance of adverse events following immunisation among individuals immunised with the COVID-19 vaccine, a cohort study in Canada. British Medical Journal Open 2022;12(1):e051254. [DOI: 10.1136/bmjopen-2021-051254] - DOI - PMC - PubMed
EUCTR‐003761‐16‐GB {published data only}
    1. EUCTR-003761-16-GB. Evaluation of pneumococcal conjugate vaccine (Prevenar) in patients with myeloma and chronic lymphocytic leukaemia - pneumococcal conjugate vaccination in haematology patients: version 1. https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-003761-16/GB (first received 14 October 2005).
Goodyear 2024 {published data only}
    1. Goodyear CS, Patel A, Barnes E, Willicombe M, Siebert S, Silva T, et al. Immunogenicity of third dose COVID-19 vaccine strategies in patients who are immunocompromised with suboptimal immunity following two doses (OCTAVE-DUO): an open label, multicentre, randomised, controlled, phase 3 trial. Lancet Rheumatology 2024;6(6):e339-51. [DOI: 10.1016/S2665-9913(24)00065-1] - DOI - PubMed
ISRCTN15354495 {published data only}
    1. ISRCTN15354495. Randomised trial optimising COVID-19 vaccination in patients with chronic health conditions and a poor response to standard vaccination. https://www.isrctn.com/ISRCTN15354495 (first received 26 July 2021).
ISRCTN15762138 {published data only}
    1. ISRCTN15762138. Vaccination response in immuno-compromised host 2. https://www.isrctn.com/ISRCTN15762138 (first received 20 December 2005).
JPRN‐jRCT1080223260 {published data only}
    1. JPRN-jRCT1080223260. A study on the long-term efficacy, safety and persistence of immune response of a vaccine against herpes zoster in older adults. https://rctportal.mhlw.go.jp/detail/jr?trial_id=jRCT1080223260 (first received 12 July 2016).
JPRN‐jRCTs031180147 {published data only}
    1. JPRN-jRCT1090220246. Efficacy of sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in the adults with immunocompromising conditions -A double blind randomized controlled trial- - CPI study [sic]. https://trialsearch.who.int/Trial2.aspx?TrialID=JPRN-jRCT1090220246 (first registered 8 April 2016).
    1. JPRN-jRCTs031180147. Efficacy of sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in the adults with immunocompromising conditions -A double blind randomized controlled trial- - CPI study [sic]. https://trialsearch.who.int/Trial2.aspx?TrialID=JPRN-jRCTs031180147 (first registered 22 February 2019).
Kazemain 2023 {published data only}
    1. Kazemain E, Figueiredo J, Skarbinski J, McBride R, Simon V, Karger AB, et al. SeroNet pooling project of immunocompromised populations. Cancer Research 2023;83(7_Supplement):798. [DOI: 10.1158/1538-7445.AM2023-798] - DOI
Leuva 2022 {published data only}
    1. Leuva H, Zhou M, Brau N, Brown ST, Mundi P, Rosenberg TM, et al. Influence of cancer on COVID-19 incidence, outcomes, and vaccine effectiveness: a prospective cohort study of U.S. veterans. Seminars in Oncology 2022;49(5):363-70. [DOI: doi:10.1053/j.seminoncol.2022.07.005 %(Leuva 2022] - PMC - PubMed
    1. Leuva H. Outcome data [personal communication]. Email to C Hirsch 19 August 2023.
Ljungman 2005 {published data only}
    1. Ljungman P, Nahi H, Linde A. Vaccination of patients with haematological malignancies with one or two doses of influenza vaccine: a randomised study. British Journal of Haematology 2005;130(1):96-8. [DOI: 10.1111/j.1365-2141.2005.05582.x] - DOI - PubMed
Molrine 1995 {published data only}
    1. Molrine DC, George S, Tarbell N, Mauch P, Diller L, Neuberg D, et al. Antibody responses to polysaccharide and polysaccharide-conjugate vaccines after treatment of Hodgkin disease. Annals of Internal Medicine 1995;123(11):828-34. [DOI: 10.7326/0003-4819-123-11-199512010-00003] - DOI - PubMed
Musto 1997 {published data only}
    1. Musto P, Carotenuto M. Vaccination against influenza in multiple myeloma. British Journal of Haematology 1997;97:504-10. - PubMed
NCT00307177 {published data only}
    1. NCT00307177. Trivalent baculovirus-expressed Influenza HA vaccine in adults with non-Hodgkin's B-cell lymphoma. https://clinicaltrials.gov/ct2/show/NCT00307177 (first received 27 March 2006).
NCT00307710 {published data only}
    1. NCT00307710. Influenza vaccination in patients receiving antineoplastic therapy for non-Hodgkin's lymphoma. https://clinicaltrials.gov/ct2/show/NCT00307710 (first received 28 March 2006).
NCT01016548 {published data only}
    1. NCT01016548. Evaluation of influenza H1N1 vaccine in adults with lymphoid malignancies on chemotherapy. https://clinicaltrials.gov/show/NCT01016548 (first received 18 November 2009).
NCT02566265 {published data only}
    1. NCT02566265. Study of high-dose influenza vaccine efficacy by repeated dosing in gammopathy patients. https://clinicaltrials.gov/study/NCT02566265 (first received 30 September 2015).
NCT04080531 {published data only}
    1. NCT04080531. Influenza vaccination for flu prevention in patients with plasma cell disorders. https://clinicaltrials.gov/study/NCT04080531 (first received 4 September 2019).
NL‐OMON32477 {published data only}
    1. NL-OMON32477. Immune response to pandemische influenza A/H1N1 vaccination in the immunocompromised. https://onderzoekmetmensen.nl/en/node/32477/pdf (first registered 3 November 2009). [CCMO REGISTER: CCMO NL30106.058.09]
Ozkurt 2016 {published data only}
    1. Ozkurt ZN, Suyanı E, Haznedar R, Yagcı M. A randomized study comparing the efficacy of three hepatitis B vaccine induction regimens in adult patients with hematological malignancies. Turkish Journal of Haematology 2016;33(3):231-5. [DOI: 10.4274/tjh.2015.0079] - DOI - PMC - PubMed
PER‐014‐11 {published data only}
    1. PER-014-11. A phase III randomized, placebo-controlled, clinical trial to study the safety and efficacy of V212 in adult patients with solid tumor or hematologic malignancy. https://trialsearch.who.int/Trial2.aspx?TrialID=PER-014-11 (first received 10 June 2011).
Poder 2023 {published data only}
    1. Poder A, Oberije J, Meyer J, Heymer P, Molrine D, Versage E, et al. Immunogenicity and safety of MF59-adjuvanted quadrivalent influenza vaccine compared with a nonadjuvanted, quadrivalent influenza vaccine in adults 50–64 years of age. Vaccines (Basel) 2023;11(10):-. [DOI: 10.3390/vaccines11101528] - DOI - PMC - PubMed
Sodhi 2015 {published data only}
    1. Sodhi JS, Raja W, Zargar SA, Showkat A, Parveen S, Nisar S, et al. The efficacy of accelerated, multiple, double-dose hepatitis B vaccine against hepatitis B virus infection in cancer patients receiving chemotherapy. Indian Journal of Gastroenterology 2015;34(5):372-9. [DOI: 10.1007/s12664-015-0595-y] - DOI - PubMed
Sun 2018 {published data only}
    1. Sun HY, Cheng A, Huang SY, Chang SY, Chen YC, Chang SC. Doses of 13-valent conjugated pneumococcal vaccine (PCV13) for patients with multiple myeloma (MM). Open Forum Infectious Diseases 2018;5:S445‐46. [DOI: 10.1093/ofid/ofy210.1272] - DOI
Svensson 2018 {published data only}
    1. NCT01892618. Pneumococcal vaccine in untreated CLL patients. https://clinicalTrials.gov/show/NCT01892618 (first received 4 July 2013).
    1. Svensson T, Kattstrom M, Hammarlund Y, Roth D, Andersson PO, Svensson M, et al. Conjugated pneumococcal vaccine triggers a better immune response than polysaccharide pneumococcal vaccine in patients with chronic lymphocytic leukemia a randomized study by the Swedish CLL group. Haematologica 2017;102:331. - PubMed
    1. Svensson T, Kattstrom M, Hammarlund Y, Roth D, Andersson PO, Svensson M, et al. Pneumococcal conjugate vaccine triggers a better immune response than pneumococcal polysaccharide vaccine in patients with chronic lymphocytic leukemia a randomized study by the Swedish CLL group. Vaccine 2018;36(25):3701-7. [DOI: 10.1016/j.vaccine.2018.05.012] - DOI - PubMed
Thangavadivel 2020 {published data only}
    1. Thangavadivel S, Zhao Q, Epperla N, Rike L, Mo X, Badawi M, et al. Early intervention with lenalidomide in patients with high-risk chronic lymphocytic leukemia. Clinical Cancer Research 2020;26(23):6187-95. [DOI: 10.1158/1078-0432.CCR-20-1280] - DOI - PMC - PubMed
Vinograd 2013 {published data only}
    1. Vinograd I, Eliakim-Raz N, Farbman L, Baslo R, Taha A, Sakhnini A, et al. Clinical effectiveness of seasonal influenza vaccine among adult cancer patients. Cancer 2013;119(22):4028-35. [DOI: 10.1002/cncr.28351] - DOI - PubMed

References to ongoing studies

ACTRN12622000454774 {published data only}
    1. ACTRN12622000454774. Influenza vaccination strategies in haematological cancers. https://anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12622000... (first received 23 March 2022).
EUCTR2012‐005713‐39 {published data only}
    1. EUCTR2012-005713-39. Response to influenza vaccination in lymphoma patients treated with CHOP and rituximab (RITUXIVAC). https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_nu... (first received 2 September 2014).
NCT05415267 {published data only}
    1. NCT05415267. Immunosuppression and COVID-19 boosters. https://clinicaltrials.gov/study/NCT05415267 (first received 8 June 2022).
NCT05417165 {published data only}
    1. NCT05417165. Anti-pneumococcal vaccine strategy in patients with chronic lymphocytic leukemia. https://clinicaltrials.gov/study/NCT05417165 (first received 9 June 2022).
NCT05556720 {published data only}
    1. Bayside Health. Bringing optimised COVID-19 vaccine schedules to immunocompromised populations (BOOST-IC): an adaptive randomised controlled clinical trial. https://clinicaltrials.gov/study/NCT05556720 (first received 23 August 2022). - PMC - PubMed
    1. Griffin DWJ, Dymock M, Wong G, Morrisey CO, Lewin SR, Cheng AC, et al. Bringing optimised COVID-19 vaccine schedules to immunocompromised populations (BOOST-IC): study protocol for an adaptive randomised controlled clinical trial. Trials 2024;25(485):-. [DOI: 10.1186/s13063-024-08315-2] - DOI - PMC - PubMed
NCT05831787 {published data only}
    1. NCT05831787. Vaccines and COVID-19 in multiple myeloma. https://clinicaltrials.gov/study/NCT05831787 (first received 20 April 2023).
NL4206 {published data only}NL4206
    1. NL4206. Response to vaccination in patients with cancer of the lymph nodes who are treated with chemotherapy. https://www.onderzoekmetmensen.nl/en/trial/27098 (first received 31 January 2014).

Additional references

Batista 2017
    1. Batista JL, Birmann BM, Epstein MM. Epidemiology of hematologic malignancies. In: Pathology and Epidemiology of Cancer. Springer, 2017:543-69. [DOI: 10.1007/978-3-319-35153-7_29] - DOI
Bitterman 2018
    1. Bitterman R, Eliakim-Raz N, Vinograd I, Zalmanovici Trestioreanu A, Leibovici L, Paul M. Influenza vaccines in immunosuppressed adults with cancer. Cochrane Database of Systematic Reviews 2018, Issue 2. Art. No: CD008983. [DOI: 10.1002/14651858.CD008983.pub3] - DOI - PMC - PubMed
Bora 2023
    1. Bora AM, Hirsch C, Kreuzberger N, Bröckelmann PJ, Mellinghoff S, Monsef I, et al. Vaccines for the prevention of infections in adults with solid tumors. Cochrane Database of Systematic Reviews 2023, Issue 5. Art. No: CD015551. [DOI: 10.1002/14651858.CD015551] - DOI - PMC - PubMed
Boutron 2022
    1. Boutron I, Page MJ, Higgins JP, Altman DG, Lundh A, Hróbjartsson A. Chapter 7: Considering bias and conflicts of interest among the included studies. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors. Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from https://training.cochrane.org/handbook.
Calabrese 2024
    1. Calabrese C, Kirchner E, Fernandez J, Calabrese L. Preventing herpes zoster in immunocompromised patients: current concepts. Celeveland Clinic Journal of Medicine 2024;91(7):437-45. [DOI: 10.3949/ccjm.91a.24019] - DOI - PubMed
Cancer Research UK 2020
    1. Cancer Research UK. Cancer incidence for common cancers: the 20 most common cancers, UK, 2016-2018. https://www.cancerresearchuk.org/health-professional/cancer-statistics/i... (accessed 22 April 2022).
CDC 2024
    1. Advisory Committee on Immunization Practices (ACIP). General best practice guidelines for immunization: best practices guidance of the Advisory Committee on Immunization Practices (ACIP). https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-co... (accessed 24 November 2024).
Chang 1976
    1. Chang HY, Rodriguez V, Narboni G, Bodey GP, Luna MA, Freireich EJ. Causes of death in adults with acute leukemia. Medicine 1976;55(3):259-68. [DOI: 10.1001/jama.1965.03090020019005] - DOI - PubMed
Chemaly 2006
    1. Chemaly RF, Ghosh S, Bodey GP, Rohatgi N, Safdar A, Keating MJ, et al. Respiratory viral infections in adults with hematologic malignancies and human stem cell transplantation recipients: a retrospective study at a major cancer center. Medicine (Baltimore) 2006;85(5):278-87. [DOI: 10.1097/01.md.0000232560.22098.4e] - DOI - PubMed
Cheuk 2011
    1. Cheuk DK, Chiang AK, Lee TL, Chan GC, Ha SY. Vaccines for prophylaxis of viral infections in patients with hematological malignancies. Cochrane Database of Systematic Reviews 2011, Issue 3. Art. No: CD006505. [DOI: 10.1002/14651858.CD006505.pub2] - DOI - PubMed
Clem 2011
    1. Clem AS. Fundamentals of Vaccine Immunology. Journal of Global Infectious Diseases January 2011;3(1):73-8. [DOI: 10.4103/0974-777X.77299] - DOI - PMC - PubMed
Cooper 2019
    1. Cooper C, Varley-Campbell J, Carter P. Established search filters may miss studies when identifying randomized controlled trials. Journal of Clinical Epidemiology 2019;112:12-9. [DOI: 10.1016/j.jclinepi.2019.04.002] - DOI - PubMed
Covidence [Computer program]
    1. Covidence. Version accessed 27 February 2023. Melbourne, Australia: Veritas Health Innovation, 2023. Available at https://www.covidence.org/.
Cronin 2018
    1. Cronin KA, Lake AJ, Scott S, Sherman RL, Noone AM, Howlader N, et al. Annual report to the nation on the status of cancer, part I: national cancer statistics. Cancer 2018;124(13):2785-800. [DOI: 10.1002/cncr.31551] - DOI - PMC - PubMed
Dagenais 2019
    1. Dagenais GR, Leong DP, Rangarajan S, Lanas F, Lopez-Jaramillo P, Gupta R, et al. Variations in common diseases, hospital admissions, and deaths in middle-aged adults in 21 countries from five continents (PURE): a prospective cohort study. Lancet 2019;395(10226):785-94. [DOI: 10.1016/S0140-6736(19)32007-0] - DOI - PubMed
Das Barshan 2024
    1. Das Barshan A, Matsumoto-Takahashi ELA. Efficacy of COVID-19 vaccines in patients with hematological malignancy compared to healthy controls: a systematic review and meta-analysis. JMA Journal 2024;7(2):153-71. [DOI: 10.31662/jmaj.2023-0171] - DOI - PMC - PubMed
Dechartres 2013
    1. Dechartres A, Trinquart L, Boutron I, Ravaud P. Influence of trial sample size on treatment effect estimates: meta-epidemiological study. British Medical Journal 2013;346:f2304. [DOI: 10.1136/bmj.f2304] - DOI - PMC - PubMed
Deeks 2024
    1. Deeks JJ, Higgins JPT, Altman DG, McKenzie JE, Veroniki AA (editors). Chapter 10: Analysing data and undertaking meta-analyses (chapter last updated November 2024). In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.5 (updated August 2024). Cochrane, 2024. Available from https://training.cochrane.org/handbook.
DGHO 2019
    1. Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie. Roadmap 2019 for research into cancer and blood diseases in Germany of the German Society for Hematology and Medical Oncology [Roadmap 2019 für die Erforschung von Krebs- und Bluterkrankungen in Deutschland]. Available at https://www.dgho.de/publikationen/stellungnahmen/klinische-forschung/for... (accessed 20 April 2022).
Dhodapkar 2021
    1. Dhodapkar MV, Dhodapkar KM, Ahmed R. Viral immunity and vaccines in hematologic malignancies: implications for COVID-19. Blood Cancer Discovery 2021;2(1):9-12. [DOI: 10.1158/2643-3230.BCD-20-0177] - DOI - PMC - PubMed
Eldridge 2021
    1. Eldridge S, Campbell M, Campbell M, Dahota A, Giraudeau B, Reeves B, et al. Revised Cochrane risk of bias tool for randomized trials (RoB 2.0). Additional considerations for cluster-randomized trials (RoB 2 CRT). Available at drive.google.com/file/d/1yDQtDkrp68_8kJiIUdbongK99sx7RFI-/view (accessed 22 April 2022).
Flowers 2007
    1. Flowers CR, Glover R, Lonial S, Brawley OW. Racial differences in the incidence and outcomes for patients with hematological malignancies. Current Problems in Cancer 2007;31(3):182-201. [DOI: 10.1016/j.currproblcancer.2007.01.005] - DOI - PubMed
Fontana 2019
    1. Fontana L, Strasfeld L. Respiratory virus infections of the stem cell transplant recipient and the hematologic malignancy patient. Infectious Disease Clinics of North America 2019;33(2):523-44. [DOI: 10.1016/j.idc.2019.02.004] - DOI - PMC - PubMed
Gebre 2021
    1. Gebre MS, Brito LA, Tostanoski LH, Edwards DK, Carfi A, Barouch DH. Novel approaches for vaccine development. Cell 2021;184(6):1589-603. [DOI: 10.1016/j.cell.2021.02.030] - DOI - PMC - PubMed
Giesen 2021
    1. Giesen N, Sprute R, Rüthrich M, Khodamoradi Y, Mellinghoff SC, Beutel G, et al. COVID-19 guideline panel of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO). 2021 update of the AGIHO guideline on evidence-based management of COVID-19 in patients with cancer regarding diagnostics, viral shedding, vaccination and therapy. European Journal of Cancer 2021;147:154-60. [DOI: 10.1016/j.ejca.2021.01.033] - DOI - PMC - PubMed
Glanville 2019
    1. Glanville J, Foxlee R, Wisniewski S, Noel-Storr A, Edwards M, Dooley G. Translating the Cochrane EMBASE RCT filter from the Ovid interface to Embase.com: a case study. Health Information & Libraries Journal 2019;36(3):264-77. [DOI: 10.1111/hir.12269] - DOI - PubMed
Government of Canada 2024
    1. Government of Canada. Immunization of immunocompromised persons: Canadian immunization guide. Available at https://www.canada.ca/en/public-health/services/publications/healthy-liv... (accessed 25 November 2024).
GRADEpro GDT [Computer program]
    1. GRADEpro GDT. Version accessed 3 March 2020. Hamilton (ON): McMaster University (developed by Evidence Prime), 2020. Available at https://www.gradepro.org.
Hersh 1965
    1. Hersh EM, Bodey GP, Nies BA, Freireich EJ. Causes of death in acute leukemia: a ten-year study of 414 patients from 1954-1963. JAMA 1965;193(2):105-9. [DOI: 10.1001/jama.1965.03090020019005] - DOI - PubMed
Higgins 2019a
    1. Higgins JPT, Eldridge S, Li T, editor(s). Chapter 23: Including variants on randomized trials (chapter last updated October 2019). In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.5 (updated August 2024). Cochrane, 2024. Available at https://training.cochrane.org/handbook.
Higgins 2019b
    1. Higgins JP, Savović J, Page MJ, Elbers RG, Sterne JAC. Chapter 8: Assessing risk of bias in a randomized trial (chapter last updated October 2019). In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.5 (updated August 2024). Cochrane, 2024. Available at https://training.cochrane.org/handbook.
Higgins 2021
    1. Higgins J, Li T, Altman D, Curtin F, Senn S. Revised Cochrane risk of bias tool for randomized trials (RoB 2) - additional considerations for crossover trials; March 2021. Available at https://drive.google.com/file/d/11LFgCuDpWk5-BvBNbHtNzbJv5-qVpTWb/view (accessed prior to 19 February 2023).
Higgins 2023
    1. Higgins JP, Li T, Deeks JJ, editor(s). Chapter 6: Choosing effect measures and computing estimates of effect (chapter last updated August 2023). In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.5. Cochrane, 2024. Available at https://training.cochrane.org/handbook.
Higgins 2024
    1. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.5 (updated August 2024). Cochrane, 2024. Available at https://training.cochrane.org/handbook.
Hirsch 2025
    1. Hirsch C, Zorger AM, Baumann M, Park YS, Bröckelmann PJ, Mellinghoff S, et al. Vaccines for preventing infections in adults with solid tumours. Cochrane Database of Systematic Reviews 2025, Issue 4. Art. No: CD015551. [DOI: 10.1002/14651858.CD015551.pub2] - DOI - PMC - PubMed
Ioannidis 2005
    1. Ioannidis JP. Why most published research findings are false. PLoS Medicine 2005;2(8). [DOI: 10.1371/journal.pmed.1004085] - DOI - PMC - PubMed
Jain 2021
    1. Jain S, Venkataraman A, Wechsler ME, Peppas NA. Messenger RNA-based vaccines: past, present, and future directions in the context of the COVID-19 pandemic. Advanced Drug Delivery Reviews 2021;179:114000. [DOI: 10.1016/j.addr.2021.114000] - DOI - PMC - PubMed
Kamboj 2024
    1. Kamboj M, Bohlke K, Baptiste DM, Dunleavy K, Fueger A, Jones L, et al. Vaccination of adults with cancer: ASCO guideline. Journal of Clinical Oncology 2024;42(14):1699-721. [DOI: 10.1200/JCO.24.00032] - DOI - PMC - PubMed
Lam 2024
    1. Lam ICH, Zhang R, Man KKC, Wong CKH, Chui CSL, Lai FTT, et al. Persistence in risk and effect of COVID-19 vaccination on long-term health consequences after SARS-CoV-2 infection. Nature Communications 2024;15(1):-. [DOI: 10.1038/s41467-024-45953-1] - DOI - PMC - PubMed
Lefebvre 2022
    1. Lefebvre C, Glanville J, Briscoe S, Featherstone R, Littlewood A, Marshall C, et al. Chapter 4: Searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available at https://training.cochrane.org/handbook.
McGill 2021
    1. McGill COVID19 Vaccine Tracker Team. COVID-19 vaccine tracker. https://covid19.trackvaccines.org/ (accessed 30 May 2022).
McGuiness 2021
    1. McGuinness LA, Higgins JP. Risk-of-bias VISualization (robvis): an R package and shiny web app for visualizing risk-of-bias assessments. Research Synthesis Methods 2021;12(1):55-61. [DOI: 10.1002/jrsm.1411] - DOI - PubMed
Mikulska 2019
    1. Mikulska M, Cesaro S, De Lavallade H, Di Blasi R, Einarsdottir S, Gallo G, et al. Vaccination of patients with haematological malignancies who did not have transplantations: guidelines from the 2017 European Conference on Infections in Leukaemia (ECIL 7). Lancet Infectious Diseases 2019;19(6):e188-99. [DOI: 10.1016/S1473-3099(18)30601-7] - DOI - PubMed
Moher 2009
    1. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Journal of Clinical Epidemiology 2009;62(10):1006-12. [DOI: 10.1371/journal.pmed.1000097] - DOI - PubMed
NCT04385160
    1. NCT04385160. Myeloproliferative neoplasms (MPN) and COVID-19 (MPN-COVID). https://clinicaltrials.gov/study/NCT04385160 (first posted 12 May 2020).
Norgaard 2006
    1. Norgaard M, Larsson H, Pedersen G, Schonheyder HC, Sorensen HT. Risk of bacteraemia and mortality in patients with haematological malignancies. Clinical Microbiology and Infection 2006;12(3):217-23. [DOI: 10.1111/j.1469-0691.2005.01298.x] - DOI - PubMed
Norris 2005
    1. Norris SL, Atkins D. Challenges in using nonrandomized studies in systematic reviews of treatment interventions. Annals of Internal Medicine 2005;142(12 Pt 2):1112-9. [DOI: 10.7326/0003-4819-142-12_part_2-200506211-00011] - DOI - PubMed
Nüesch 2010
    1. Nüesch E, Trelle S, Reichenbach S, Rutjes AW, Tschannen B, Altman DG. Small study effects in meta-analyses of osteoarthritis trials: meta-epidemiological study. British Medical Journal 2010;341:c3515. [DOI: 10.1136/bmj.c3515] - DOI - PMC - PubMed
Ouzzani 2016
    1. Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan—a web and mobile app for systematic reviews. Systematic Reviews 2016;5(210):-. [DOI: 10.1186/s13643-016-0384-4] - DOI - PMC - PubMed
Page 2020
    1. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. British Medical Journal 2021;372:n71. [DOI: 10.1136/bmj.n71] - DOI - PMC - PubMed
Page 2024
    1. Page MJ, Higgins JP, Sterne JAC. Chapter 13: Assessing risk of bias due to missing evidence in a meta-analysis. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.5. Cochrane, 2024. Available at https://training.cochrane.org/handbook.
Piechotta 2022
    1. Piechotta V, Mellinghoff S, Hirsch C, Brinkmann A, Iannizzi C, Kreuzberger N, et al. Effectiveness, immunogenicity, and safety of COVID-19 vaccines for individuals with hematological malignancies: a systematic review. Blood Cancer Journal 2022;12:86. [DOI: 10.1038/s41408-022-00684-8] - DOI - PMC - PubMed
Plotkin 2010
    1. Plotkin SA. Correlates of protection induced by vaccination. Clinical and Vaccine Immunology 2010;17(7):1055-65. [DOI: 10.1128/CVI.00131-10] - DOI - PMC - PubMed
Poland 2020
    1. Poland GA, Ovsyannikova IG, Kennedy RB. SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates. Lancet 2020;396(1026):1595-606. [DOI: 10.1016/S0140-6736(20)32137-1] - DOI - PMC - PubMed
Reeves 2019
    1. Reeves BC, Deeks JJ, Higgins JP, Shea B, Tugwell P, Wells GA. Chapter 24: Including non-randomized studies on intervention effects (last updated October 2019). In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.5 (updated August 2024). Cochrane, 2024. Available at https://training.cochrane.org/handbook.
RevMan 2024 [Computer program]
    1. Review Manager (RevMan). Version 8.13.0. The Cochrane Collaboration, 2024. Available at https://revman.cochrane.org.
Rieger 2018
    1. Rieger CT, Liss B, Mellinghoff S, Buchheidt D, Cornely OA, Egerer G, et al. Anti-infective vaccination strategies in patients with hematologic malignancies or solid tumors - guideline of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO). Annals of Oncology 2018;29(6):1354-65. [DOI: 10.1093/annonc/mdy117] - DOI - PMC - PubMed
Rinaldi 2022
    1. Rinaldi I, Pratama S, Wiyono L, Tandaju JR, Wardhana IL, Winston K. Efficacy and safety profile of COVID-19 mRNA vaccine in patients with hematological malignancies: systematic review and meta-analysis. Frontiers in Oncology 2022;12:951215. [DOI: 10.3389/fonc.2022.951215] - DOI - PMC - PubMed
Rolston 2017
    1. Rolston KV. Infections in cancer patients with solid tumors: a review. Infectious Diseases and Therapy 2017;6(1):69-83. [DOI: 10.1007/s40121-017-0146-1] - DOI - PMC - PubMed
Rüthrich 2022
    1. Rüthrich MM, Giesen N, Mellinghoff SC, Rieger CT, Lilienfeld-Toal M. Cellular immune response after vaccination in patients with cancer: review on past and present experiences. Vaccines 2022;10(2):182. [DOI: 10.3390/vaccines10020182] - DOI - PMC - PubMed
Santesso 2020
    1. Santesso N, Glenton C, Dahm P, Garner P, Akl A, Alper B, et al. GRADE guidelines 26: informative statements to communicate the findings of systematic reviews of interventions. Journal of Clinical Epidemiology 2020;119:126-35. [DOI: 10.1016/j.jclinepi.2019.10.014] - DOI - PubMed
Schünemann 2019
    1. Schünemann HJ, Cuello C, Akl EA, Mustafa RA, Meerpohl JJ, Thayer K, et al. GRADE guidelines: 18. How ROBINS-I and other tools to assess risk of bias in nonrandomized studies should be used to rate the certainty of a body of evidence. Journal of Clinical Epidemiology 2019;111:105-14. [DOI: 10.1016/j.jclinepi.2018.01.012] - DOI - PMC - PubMed
Schünemann 2023
    1. Schünemann HJ, Vist GE, Higgins JPT, Santesso N, Deeks JJ, Glasziou P, et al. Chapter 15: Interpreting results and drawing conclusions (last updated August 2023). In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.5. Cochrane, 2024. Available from https://training.cochrane.org/handbook.
Schünemann 2025
    1. Schünemann HJ, Higgins JP, Vist GE, Glasziou P, Akl EA, Skoetz N, et al. Chapter 14: Completing 'Summary of findings' tables and grading the certainty of the evidence (chapter last updated May 2025). In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.5.1. Cochrane, 2024. Available at https://training.cochrane.org/handbook.
Stemler 2020
    1. Stemler J, Koehler P, Maurer C, Müller C, Cornely OA. Antifungal prophylaxis and novel drugs in acute myeloid leukemia: the midostaurin and posaconazole dilemma. Annals of Hematology 2020;99(7):1429-40. [DOI: 10.1007/s00277-020-04107-1] - DOI - PMC - PubMed
Sterne 2016
    1. Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 2016;355:i4919. [DOI: 10.1136/bmj.i4919] - DOI - PMC - PubMed
Sterne 2019
    1. Sterne JA, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 2019;366:l4898. [DOI: ] - PubMed
Teh 2022
    1. Teh JSK, Coussement J, Neoh ZCF, Spelman T, Lazarakis S, Slavin MA, et al. Immunogenicity of COVID-19 vaccines in patients with hematologic malignancies: a systematic review and meta-analysis. Blood Advances April 2022;6(7):2014-34. [DOI: 10.1182/bloodadvances.2021006333] - DOI - PMC - PubMed
Teh 2024
    1. Teh BW, Mikulska M, Averbuch D, De la Camara R, Hirsch HH, Akova M, et al. Consensus position statement on advancing the standardised reporting of infection events in immunocompromised patients. Lancet Infectious Diseases 2024;24(1):e59-e68. [DOI: 10.1016/S1473-3099(23)00377-8] - DOI - PubMed
Tsigrelis 2016
    1. Tsigrelis C, Ljungman P. Vaccinations in patients with hematological malignancies. Blood Reviews 2016;30(2):139-47. [DOI: 10.1016/j.blre.2015.10.001] - DOI - PubMed
Vanaparthy 2021
    1. Vanaparthy R, Mohan G, Vasireddy D, Atluri P. Review of COVID-19 viral vector-based vaccines and COVID-19 variants. Infezioni in Medicina 2021;10:328-38. [DOI: 10.53854/liim-2903-3] - DOI - PMC - PubMed
Waffenschmidt 2020
    1. Waffenschmidt S, Navarro-Ruan T, Hobson N, Hausner E, Sauerland S, Haynes RB. Development and validation of study filters for identifying controlled non-randomized studies in PubMed and Ovid MEDLINE. Research Synthesis Methods 2020;11(5):617-26. [DOI: 10.1002/jrsm.1425] - DOI - PubMed
Wallace 2017
    1. Wallace BC, Noel-Storr AH, Marshall IJ, Cohen AM, Smalheiser NR, et al. Identifying reports of randomized controlled trials (RCTs) via a hybrid machine learning and crowdsourcing approach. Journal of the American Medical Informatics Association 2017;24(6):1165-8. - PMC - PubMed
WHO 2022
    1. World Health Organization. Cancer. https://www.who.int/health-topics/cancer (accessed 22 April 2022).
Zeidner 2018
    1. Zeidner JF, Roy D, Perl A, Gojo I. Chapter 29: myeloid malignancies. In: American Cancer Society, editors(s). The American Cancer Society's Oncology in Practice: Clinical Management. Wiley, 2018:397-421. [DOI: 10.1002/9781118592168.ch29] - DOI
Zheng 2021
    1. Zheng Y, Chen Y, Yu K, Yang Y, Wang X, Yang X, et al. Fatal infections among cancer patients: a population-based study in the United States. Infectious Diseases and Therapy 2024;10(2):871-95. [DOI: 10.1007/s40121-021-00433-7] - DOI - PMC - PubMed

References to other published versions of this review

Hirsch 2023
    1. Hirsch C, Bröckelmann P, Mellinghoff S, Bora A, Kreuzberger N, Monsef I, et al. Vaccines for the prevention of infections in adults with haematological malignancies. Cochrane Database of Systematic Reviews 2023, Issue 2. Art. No: CD015530. [DOI: 10.1002/14651858.CD015530] - DOI - PMC - PubMed

Associated data

LinkOut - more resources